Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00227188
First received: September 13, 2005
Last updated: November 28, 2012
Last verified: November 2012

September 13, 2005
November 28, 2012
May 2003
December 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00227188 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Samples without DNA

Non-Probability Sample

All public and private hospitals with a pediatric department belonging to one of the two autonomous communities.

Invasive Pneumococcal Disease
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Other Name: PREVNAR
1
Children from 0-5 years of age evaluated for IPD
Intervention: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
408
December 2005
December 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
  • Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.
Both
up to 5 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00227188
0887-101317
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP